Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. A big welcome to everyone coming to Chicago for ASCO this weekend. Say hi if you’re attending our STAT event on Friday night!

The need-to-know this morning

• The U.S. government is nearing an agreement to bankroll a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, according to the Financial Times.

Trade group fights FDA’s plan to regulate lab-developed tests

A group representing clinical labs across the U.S. sued the FDA yesterday over the agency’s plan to regulate lab-developed tests. It’s the first lawsuit challenging the new rule.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In